Cargando…
Coagulation factor inhibitors in COVID‐19: From SARS‐CoV‐2 vaccination to infection
BACKGROUND: Recent reports have highlighted patients with COVID‐19 and vaccine recipients diagnosed with coagulation factor inhibitors. This is challenging. as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection has been identified as a prothrombotic risk factor, with heparin trea...
Autores principales: | Jacobs, Jeremy W., Adkins, Brian D., Walker, Shannon C., Booth, Garrett S., Wheeler, Allison P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010729/ https://www.ncbi.nlm.nih.gov/pubmed/35441121 http://dx.doi.org/10.1002/rth2.12700 |
Ejemplares similares
-
Inactivated vaccine for SARS-CoV-2
por: Risson, Emma
Publicado: (2020) -
Anti-SARS-CoV-2 vaccine in liver transplantation
por: Kotsiliti, Eleni
Publicado: (2022) -
SARS-CoV-2 vaccine safe for young patients
por: Onuora, Sarah
Publicado: (2022) -
Soluble ACE2 in SARS-CoV-2 infection
por: Allison, Susan
Publicado: (2021) -
The Uro-oncology Patient and Vaccination Against SARS-CoV-2
por: Rodriguez Socarrás, Moises, et al.
Publicado: (2021)